Healthcare / BiotechnologyNasdaqCM
$11.26
-0.71 (-5.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.8M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$299M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-54.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-52.6M · FCF $-35.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | $0.00 | — | $158926.00 | $1.2M | $363781.00 | $103167.00 |
| Net Income | $-52.6M | $-52.6M | $-17.6M | $-7.7M | $-11.0M | $-32.5M | $-9.9M | $-8.4M | $-14.1M | $-8.8M | $-43.9M | — | $-19.5M | $-9.4M | $-15.7M | $10.4M |
| EBITDA | $-52.6M | $-52.6M | $-17.6M | $-7.7M | $-10.9M | $-32.7M | $9.9M | $-8.6M | $-6.9M | $-9.2M | $-52.6M | — | $-16.5M | $-5.0M | $-8.0M | $10.9M |
| EPS | -1.34 | -1.34 | -1.15 | -31.04 | -600.71 | — | — | — | — | — | — | — | -86720.00 | -213760.00 | -450240.00 | -288000.00 |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | -65.5% | 4.2% | 13.5% | 100.0% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | -10452.1% | -435.7% | -2259.7% | 10238.4% |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | -12296.2% | -790.6% | -4319.2% | 10127.6% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | — | — | — | 0.06 | 0.54 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 14.52 | 14.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-35.8M | $-35.8M | $-14.8M | $-5.9M | $-11.4M | $-10.9M | $-9.3M | $-7.6M | $-5.5M | $-12.1M | $-15.9M | — | $-9.3M | $-4.9M | $-8.3M | $-8.6M |
| Returns | ||||||||||||||||
| ROE | -54.2% | -54.2% | -19.1% | -95.2% | -740.1% | -765.1% | -213.0% | -222.5% | -120.2% | -99.5% | -256.3% | — | -23.6% | 529.6% | 4540.6% | -280.5% |
| Valuation | ||||||||||||||||
| P/B | 4.55 | 4.55 | 1.03 | 0.41 | 2.24 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | — | — | -86.7% | 227.4% | 252.6% | — |
| EPS Growth | -16.5% | -16.5% | 96.3% | 94.8% | — | — | — | — | — | — | — | — | 59.4% | 52.5% | -56.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+85.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.15 → -1.34
Residual
+85.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.